BiomedAI.com is developing an advanced artificial intelligence platform to predict and accelerate the discovery of novel drugs for the treatment and prevention of neurodegenerative, metabolic, and cardiovascular diseases.

The platform is built upon Dr. Lloyd Tran’s Unified Theory, which proposes that disorders such as Alzheimer’s disease, obesity, diabetes, stroke, and cardiovascular disease are interconnected manifestations of common biological dysfunctions rather than isolated conditions. Key shared mechanisms include chronic inflammation, mitochondrial dysfunction, impaired energy metabolism, vascular injury, and cellular senescence.

By integrating multi-omics data, real-world clinical evidence, molecular network modeling, biomarker discovery, and machine learning, BiomedAI aims to identify predictive disease signatures, novel therapeutic targets, and drug candidates capable of modifying multiple disease pathways simultaneously.

The platform leverages insights generated from the successful drug development pipeline at Biomed Industries, Inc., including NA-831 for Alzheimer’s disease, NA-931 for obesity and metabolic disorders, NA-911 for stroke, and other investigational therapies currently advancing through clinical development. These programs provide valuable clinical and translational datasets that continuously refine AI prediction models and therapeutic hypotheses.

Through the combination of artificial intelligence, systems biology, and clinical validation, BiomedAI seeks to create a predictive drug discovery ecosystem capable of delivering innovative therapies and preventive solutions that address the root causes of chronic diseases and improve global health outcomes.